Silica nanostructures are widely investigated for theranostic applications, since relatively mild and easy synthetic methods allow the fabrication of multi-compartment nanoparticles (NPs) and to finely modulate their properties. Here, we report the optimization of a synthetic strategy leading to brightly fluorescent silica NPs with a high loading ability – up to 45 molecules per NP – of Sorafenib, a small molecule acting as antiangiogenic drug. We demonstrate that these NPs can efficiently release the drug and they are able to inhibit endothelial cell proliferation, migration and network formation. Their lyophilization can endow them with long shelf stability while, once in solution, they show a much slower release compared to analogous micellar systems. Interestingly, Sorafenib released from PluS NPs completely prevented endothelial cell responses and post-receptor MAPK signaling ignited by VEGF, one of the major player of tumor angiogenesis. Our results indicate that these theranostic systems represent a promising structure for anti-cancer applications since NPs alone have no cytotoxic effect on cultured endothelial cells, a cell type to which drugs and exogenous material are always in contact once delivered
Palomba, F., Genovese, D., Rampazzo, E., Zaccheroni, N., Prodi, L., Morbidelli, L. (2019). PluS Nanoparticles Loaded with Sorafenib: Synthetic Approach and Their Effects on Endothelial Cells. ACS OMEGA, 4(9), 13962-13971 [10.1021/acsomega.9b01699].
PluS Nanoparticles Loaded with Sorafenib: Synthetic Approach and Their Effects on Endothelial Cells
Morbidelli, Lucia
2019-01-01
Abstract
Silica nanostructures are widely investigated for theranostic applications, since relatively mild and easy synthetic methods allow the fabrication of multi-compartment nanoparticles (NPs) and to finely modulate their properties. Here, we report the optimization of a synthetic strategy leading to brightly fluorescent silica NPs with a high loading ability – up to 45 molecules per NP – of Sorafenib, a small molecule acting as antiangiogenic drug. We demonstrate that these NPs can efficiently release the drug and they are able to inhibit endothelial cell proliferation, migration and network formation. Their lyophilization can endow them with long shelf stability while, once in solution, they show a much slower release compared to analogous micellar systems. Interestingly, Sorafenib released from PluS NPs completely prevented endothelial cell responses and post-receptor MAPK signaling ignited by VEGF, one of the major player of tumor angiogenesis. Our results indicate that these theranostic systems represent a promising structure for anti-cancer applications since NPs alone have no cytotoxic effect on cultured endothelial cells, a cell type to which drugs and exogenous material are always in contact once deliveredFile | Dimensione | Formato | |
---|---|---|---|
acsomega.9b01699.pdf
accesso aperto
Descrizione: Paper
Tipologia:
PDF editoriale
Licenza:
PUBBLICO - Pubblico con Copyright
Dimensione
4.97 MB
Formato
Adobe PDF
|
4.97 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
https://hdl.handle.net/11365/1079433